FOFA 8-K
Family Office Of America, Inc. (FOFA)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices)
Registrant’s
telephone number, including area code: Telephone: :
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| OTC Pink marketplace |
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 23, 2023, Dr. Robert Bilkovski, the Chief Scientific Officer of Qualis Innovations, Inc. (the “Company”), notified the Company of his decision to resign, effective immediately, from any and all offices he may hold with the Company, including Chief Scientific Officer of the Company. Dr. Bilkovsk.i’s resignation was to pursue other business opportunities and did not result from any disagreement with the Company, the Company’s Board of Directors, or the Company’s management on any matter relating to the Company’s operations, policies or practices.
| Exhibit No | Description | |
| 1 | ||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
| -2- |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| QUALIS INNOVATIONS, INC. | ||
| By: | /s/ Jim Holt | |
| Name: | Jim Holt | |
| Date: | January 23, 2023 | |
| -3- |
Exhibit 1
 |
|
| Notice |
Robert Bilkovski, MD, MBA President RNB Ventures Consulting Inc. 12191 W. Linebaugh Avenue Unit 687 | |
| Tampa, FL 33626 | |
| January 23, 2023 |
Qualis Innovations, Inc.
225 Wilmington West Chester Pike
Suite 200 # 145
Chadds Ford, Pennsylvania 19317
Re: Resignation as a Member of the Board of Directors and as an Officer
Ladies and Gentlemen:
Please be advised that I hereby resign from any and all offices I may hold with the Company, including as Chief Scientific Officer of the Company, and any of its subsidiaries, if any, effective as of 04:00 p.m. Eastern Time on the date first written above (the “Effective Time”).
I expect that all of my rights to indemnification and exculpation (including the advancement of expenses) from liabilities for acts or omissions occurring at or prior to the Effective Time now existing in favor of the current or former directors and officers of the Company (and its subsidiaries, as applicable) as provided in the Company’s (and its subsidiaries, as applicable) certificate of incorporation and bylaws shall continue in full force and effect in accordance with their terms and the Company (and its subsidiaries, as applicable) shall honor such rights. In addition, I expect that the Company will maintain appropriate levels of directors and officers insurance policies in full force and effect at all times and, if appropriate, purchase tail policies.
| Sincerely, | |
| /s/ Robert Bilkovski, MD, MBA | |
| Robert Bilkovski, MD, MBA |
RNB Ventures Consulting Inc.
12191 W. Linebaugh Ave. Unit 687
Tampa, FL 33626